Over the last few years, two compounds have dominated the research on incretin-based metabolic therapies: semaglutide and tirzepatide. Both are well studied, both have produced striking results in clinical trials, and both are now widely used as reference compounds in metabolic research. The key scientific difference between them is the number of receptors they act on, and that difference has shaped a large body of research.
One receptor or two
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone involved in insulin release, appetite signalling and the rate at which the stomach empties.
Tirzepatide acts on the GLP-1 receptor too, but it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone with its own effects on insulin secretion and on how fat tissue handles energy. Combining the two in one molecule was the idea behind the “dual agonist” approach, sometimes called a “twincretin”.
What the trials have shown
Tirzepatide was studied in the SURPASS programme for type 2 diabetes and the SURMOUNT programme for obesity. In SURMOUNT-1, published in 2022, adults with obesity on the highest dose lost an average of around 21% of their body weight over 72 weeks.
The most direct comparison came from SURMOUNT-5, a head-to-head trial against semaglutide. Participants on tirzepatide lost an average of around 20% of their body weight, compared with around 14% on semaglutide over the same period. Tirzepatide also produced larger reductions in waist circumference.
These results have made tirzepatide one of the standard comparators in metabolic research, and they have raised a broader scientific question: how much of the extra effect comes from GIP signalling, and how much from the way the molecule balances the two receptors?
Why this matters for researchers
For laboratories, tirzepatide is valuable precisely because it sits between single and triple agonists. It allows researchers to study:
- How dual receptor activation compares with GLP-1 activation alone in cell and tissue models.
- The role of GIP signalling in fat tissue and energy balance.
- How tirzepatide compares with newer triple agonists such as retatrutide, which adds the glucagon receptor.
A clear introduction to the compound, its mechanism and how it fits alongside other incretin peptides is available in the Tirzepatide UK research guide.
Choosing a research-grade supply
As with any research peptide, the value of the data depends on the quality of the compound. Researchers should look for:
- Independent third-party testing, ideally from a recognised lab such as Janoshik, with results tied to the specific batch.
- Purity of 98% or higher and a stated peptide content.
- UK stock and fast, tracked delivery to protect the lyophilised powder.
- Clear “research use only” labelling.
UK suppliers such as Revial Labs tirzepatide offer 20mg and 30mg vials with published Janoshik certificates and same-day dispatch.
Looking ahead
The success of dual agonism has opened the door to the next generation of compounds, including triple agonists and combinations with other hormone pathways. Tirzepatide remains a cornerstone of this research, both as a compound of interest in its own right and as the benchmark against which newer molecules are measured.
This article is for information only. Tirzepatide supplied by research chemical companies is for laboratory research use only and is not for human consumption.See More